The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension

被引：0
|
作者：
Samantha L. Wronski
Margaret Mordin
Kim Kelley
Rebekah H. Anguiano
Peter Classi
Eric Shen
Scott Manaker
机构：
[1] RTI Health Solutions,Department of Pharmacy Practice
[2] RTI Health Solutions,Department of Medicine
[3] Rx Trusted Advisors,undefined
[4] University of Illinois at Chicago,undefined
[5] United Therapeutics,undefined
[6] Perelman School of Medicine at the University of Pennsylvania,undefined
来源：
Lung | 2020年 / 198卷
关键词：
PAH; Noninvasive endpoint; Risk assessment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 86
页数：21
相关论文
共 50 条
  • [1] The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
    Wronski, Samantha L.
    Mordin, Margaret
    Kelley, Kim
    Anguiano, Rebekah H.
    Classi, Peter
    Shen, Eric
    Manaker, Scott
    LUNG, 2020, 198 (01) : 65 - 86
  • [2] Long-term therapeutic outcomes in pulmonary arterial hypertension
    Galie, Nazzareno
    Hirani, Naushad
    Manes, Alessandra
    Romanazzi, Serena
    Palazzini, Massimiliano
    Negro, Luca
    Branzi, Angelo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S11 - S18
  • [3] Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension
    文莉
    China Medical Abstracts(Internal Medicine), 2014, 31 (03) : 160 - 161
  • [4] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Calcaianu, Mihaela
    Canuet, Matthieu
    Enache, Irina
    Kessler, Romain
    PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
  • [5] Characterization of long-term interleukin-33 administration as an animal model of pulmonary arterial hypertension
    Ikutani, Masashi
    Shimizu, Shoichi
    Okada, Koki
    Imami, Koshi
    Inagaki, Tadakatsu
    Nakaoka, Yoshikazu
    Osada, Yoshio
    Nakae, Susumu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 734
  • [6] Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension
    Caccamo, Marco
    Harrell, Frank E. E.
    Hemnes, Anna R. R.
    PULMONARY CIRCULATION, 2023, 13 (03)
  • [7] Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database
    Suzuki, Koji
    Yagi, Tatsuya
    Kawakami, Junichi
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (07) : 4981 - 4992
  • [8] Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
    Benza, Raymond L.
    Seeger, Werner
    McLaughlin, Vallerie V.
    Channick, Richard N.
    Voswinckel, Robert
    Tapson, Victor F.
    Robbins, Ivan M.
    Olschewski, Horst
    Rubin, Lewis J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12) : 1327 - 1333
  • [9] Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
    Benza, Raymond L.
    Chin, Kelly M.
    Gaine, Sean
    Galie, Nazzareno
    Hoeper, Marius M.
    Lang, Irene M.
    V. McLaughlin, Vallerie
    Sitbon, Olivier
    Doad, Gurinderpal
    Yen, Joseph
    Tang, Xiaoqin
    Tapson, Victor
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (12) : 1998 - 2007
  • [10] The combination of supervised and unsupervised learning based risk stratification and phenotyping in pulmonary arterial hypertension—a long-term retrospective multicenter trial
    Thomas Sonnweber
    Piotr Tymoszuk
    Regina Steringer-Mascherbauer
    Elisabeth Sigmund
    Stephanie Porod-Schneiderbauer
    Lisa Kohlbacher
    Igor Theurl
    Irene Lang
    Günter Weiss
    Judith Löffler-Ragg
    BMC Pulmonary Medicine, 23
12345